Zurich, SWITZERLAND – 22 December 2016 -- The Board of Directors of Sequana Medical AG ("Sequana Medical" or the "Company") announces with great sadness, the sudden death of its Founder, President and Chief Executive Officer, Noel L. Johnson, Ph. D.
Zurich, SWITZERLAND – 11 July 2016 – Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems that manage fluid build-up occurring in patients with liver disease, heart disease and certain cancers, announced today the appointment of Ian Crosbie as Chief Financial Officer.
Former Bayer and Pharmacia Senior Executive Rolf A. Classon joins the Sequana Medical AG Board as Chairman
Zurich, SWITZERLAND – 01 July 2016 – Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative, implantable pump systems to manage fluid build-up in patients with liver disease, congestive heart failure and certain cancers, announced today that Rolf A. Classon, former top executive of Bayer AG and Pharmacia AB, has been appointed Chairman of the Board of Directors.
Transaction Includes New Investors Salus Partners and Quest for Growth
Sequana Medical AG, a privately held medical device company focused on the development and commercialization of innovative implantable pump systems that manage excess fluid within the body, announced today that it has raised CHF 9 million ($9.3 million) in a Series C extension round. Existing investors including NeoMed Management AS, VI Partners AG, Biomed Invest AG, Capricorn Health-tech Fund, Entrepreneurs Fund and Life Science Partners participated for a total of CHF 5.3M, with a further CHF 3.7M raised from new investors including Salus Partners SA and Quest for Growth NV. Sequana Medical will use these funds to expand current business for its proven fluid management systems through new indications in heart disease and to pursue U.S. marketing approvals.
Sequana Medical presented the alfapump® system at this year’s Viszeralmedizin Congress in Leipzig, Germany
Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre.
Sequana Medical presents exciting clinical updates on the alfapump® System at this year’s International Liver Congress in Vienna.
Sequana Medical is delighted to be attending this year’s International Liver Congress in Vienna to present alfapump with DirectLink Technology.
Sequana Medical is pleased to announce the appointment of Medinistros SAS as exclusive distributor for the alfapump system in Colombia.
Sequana Medical supports Bristol hepatologist Dr Anne McCune’s Sahara Challenge in aid of the British Liver Trust
Sequana Medical is proud to support Dr Anne McCune in her brave trek across the Sahara in aid of the British Liver Trust.
Sequana Medical’s new alfapump® with DirectLink Technology improves the care of patients with challenging refractory ascites
Technological advances in Sequana Medical’s alfapump system will allow patients and their doctors to better manage the distressing symptoms of refractory ascites. With enhanced communications enabled by the new DirectLink Technology, clinicians will now be able to monitor the alfapump remotely.
The Financial Times, one of the world’s leading business news organisations, reported today that Sequana Medical has raised $26 million in a Series C financing round.